Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.

ABSTRACT: While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT_2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test sessions spaced 2 weeks apart. Subjects maintained headache diaries starting 2 weeks before the first session until 2 weeks after the second session. Physiological and psychological drug effects were monitored during sessions and several follow-up contacts with subjects were carried out to assure safety of study procedures. Ten subjects were included in the final analysis. Over the 2-week pe

SUBMITTER: Schindler EAD 

PROVIDER: S-EPMC8116458 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature